Tianjin Development Unit to Invest 174 Million Yuan in Biotech Fund
MT Newswires Live
Aug 22
Tianjin Development (HKG:0882) said its indirect non-wholly owned subsidiary Lisheng Pharmaceutical (SHE:002393) plans to commit 173.8 million yuan to a new private equity fund focused on health and biotechnology, according to a Friday Hong Kong bourse filing.
The proposed fund will have a total capital commitment of 500 million yuan, with Lisheng contributing 34.8% as a limited partner.
Other participants include CCB Investment, TEDA Private Equity, TEDA International, Guoxin Fund, and CCB Strategic Fund.
The five-year fund will target opportunities across China's health and biotech sectors, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.